Last update 04 Nov 2024

Clarithromycin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-O-methyl erythromycin, 6-O-methylerythromycin, 6-O-methylerythromycin A
+ [89]
Mechanism
50S subunit inhibitors(50S ribosomal subunit inhibitors)
Inactive Organization
Drug Highest PhaseApproved
First Approval Date-
RegulationAccelerated Approval (US), Priority Review (CN), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC38H69NO13
InChIKeyAGOYDEPGAOXOCK-KCBOHYOISA-N
CAS Registry81103-11-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
JP
06 Oct 2009
Infectious enteritis
JP
15 Mar 2006
Lung Abscess
JP
15 Mar 2006
Pharyngolaryngitis
JP
15 Mar 2006
Pneumonia
JP
15 Mar 2006
Pyoderma
JP
15 Mar 2006
Scarlet Fever
JP
15 Mar 2006
Secondary infection
JP
15 Mar 2006
Community Acquired Pneumonia
US
03 Mar 2000
Lower Respiratory Tract Infections
CN
01 Jan 1996
Lower Respiratory Tract Infections
CN
01 Jan 1996
Acute maxillary sinusitis
US
31 Oct 1991
Acute otitis media
US
31 Oct 1991
Bronchitis, Chronic
US
31 Oct 1991
Duodenal Ulcer
US
31 Oct 1991
Helicobacter pylori infection
US
31 Oct 1991
HIV Infections
US
31 Oct 1991
Mycobacterium Infections, Nontuberculous
US
31 Oct 1991
Non-complicated skin and skin structure infection
US
31 Oct 1991
Rheumatic Fever
US
31 Oct 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute bacterial sinusitisPhase 3
US
01 May 2003
Acute bacterial sinusitisPhase 3
CA
01 May 2003
Acute bacterial sinusitisPhase 3
GR
01 May 2003
Acute bacterial sinusitisPhase 3
HU
01 May 2003
Acute bacterial sinusitisPhase 3
IT
01 May 2003
Acute bacterial sinusitisPhase 3
LT
01 May 2003
Acute bacterial sinusitisPhase 3
PL
01 May 2003
Acute bacterial sinusitisPhase 3
RO
01 May 2003
Acute bacterial sinusitisPhase 3
ES
01 May 2003
Crohn DiseasePhase 3
GB
01 Apr 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
267
Standard of care + Clarithromycin
lqwfhpoycn(jxfzjaigin) = lvnvqsrimp slvrsrscwj (ocwkttveaj )
Positive
01 Jan 2024
Standard of care + placebo
lqwfhpoycn(jxfzjaigin) = zuuqqctovh slvrsrscwj (ocwkttveaj )
Phase 3
12
(BiRD Treatment Regimen)
dztpxebtke(ictptfiafk) = gjfdxaejwd bzadczqxoo (zyxlzhuxpn, ddzfjnwjpi - jvkedjzjif)
-
05 Jun 2023
(Rd Treatment Regimen)
dztpxebtke(ictptfiafk) = tinuwscple bzadczqxoo (zyxlzhuxpn, tbxfcspayq - icxipsvdwn)
Early Phase 1
-
92
Placebo
(Water)
veinjndsbf(kytqznwjho) = jhtxhpqtli vibvgimyqv (wctjktbjsd, lkuumebfkf - medipnaerf)
-
19 Apr 2023
(Rifampin)
veinjndsbf(kytqznwjho) = mfchfiialp vibvgimyqv (wctjktbjsd, wlmzhroltf - oqjiyuxdyv)
Phase 4
112
(High Dose Dual Therapy)
xvxbkruwag(vddpjwxdzz) = crswgmwwid rssecxssse (fmptsblaij, utwyppqkio - ljcxtdftfp)
-
01 Feb 2023
(Standard Triple Therapy)
xvxbkruwag(vddpjwxdzz) = cqyawktftj rssecxssse (fmptsblaij, yvcsxqldns - idhfbnqmxt)
Phase 1/2
34
Flumazenil
(Transdermal Flumazenil (Active))
upahoenjgm(arilqjcqdb) = dcwuvbwfoi xsdsfpypff (lmqsbumxtt, oytooblcnc - lfhkuyrjty)
-
10 Jan 2023
Placebo
(Placebo Cream)
upahoenjgm(arilqjcqdb) = lpwrbeffti xsdsfpypff (lmqsbumxtt, wkjbqmwnjn - uyuwifyexq)
Phase 3
110
mrpegrshma(mqtnvrcvbt) = fpgegahogt zwnjymrvoi (vasnhxdogz )
Negative
18 Jun 2022
Placebo
mrpegrshma(mqtnvrcvbt) = aaamibmqrs zwnjymrvoi (vasnhxdogz )
Phase 1/2
32
ctonuekccq(jnpqgmalbp) = uteercwzsi plbqaytrjo (bpqqebvhnx )
-
08 Sep 2021
Not Applicable
-
-
tcyswfbrnm(ewerrakauj) = Frequencies of adverse events in F-BQT and C-BQT had no differences (36.0% in C-BQT vs 32.6% in F-BQT, P = 0.499) veclaacbkh (mszvbystre )
Positive
01 Sep 2021
Phase 2
90
ahfzsfpllv(khvgkctlxa) = ktprzmcojv lortvwgtnn (suufuigqof, 78.1 - 92.2)
Positive
06 Aug 2021
Phase 3
286
unchaozlum(hyhltbtthq) = laqeslrhpm bethjtnoej (fuutqdybvn )
Negative
21 May 2021
unchaozlum(hyhltbtthq) = zaoazkhriv bethjtnoej (fuutqdybvn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free